Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

Sergiu is a news reporter who has covered the latest cybersecurity and technology developments for over a decade. Email or Twitter DMs for tips. Microsoft is introducing a new scareware sensor for the ...